metabolic associated fatty liver disease
Showing 1 - 7 of 7
Metabolic Associated Fatty Liver Disease Trial in Mexico (LUDLEV®300 mg/46.2 mg, Placebo)
Recruiting
- Metabolic Associated Fatty Liver Disease
- LUDLEV®300 mg/46.2 mg
- Placebo
-
Mexico, Veracruz, MexicoAna Delfina Cano Contreras
Jun 12, 2023
Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- dapagliflozin (Forxiga)
- (no location specified)
Mar 13, 2023
SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- Recombinant protein vaccine and adenovirus vector vaccine
- (no location specified)
Feb 12, 2023
MAFLD in Type 2 Diabetes in Jiangsu Province of China
Recruiting
- Type 2 Diabetes Mellitus in Remission
- Metabolic Associated Fatty Liver Disease
- Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
-
Nanjing, Jiangsu, ChinaZhongda Hospital, Medical School, Southeast University
Oct 24, 2022
Metabolic Associated Fatty Liver Disease Trial in Guangzhou (Dietitian led life style modification intervention, Conventional
Recruiting
- Metabolic Associated Fatty Liver Disease
- Dietitian led life style modification intervention
- Conventional care (control)
-
Guangzhou, Guangdong, ChinaHepatology Unit, Department of Infectious Diseases, Nanfang Hosp
Apr 29, 2021
Stratification Tool for Predicting Metabolic Outcomes
Completed
- Metabolic Associated Fatty Liver Disease
- the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
- (no location specified)
Feb 16, 2021
Metabolic Associated Fatty Liver Disease in China
Recruiting
- Metabolic Associated Fatty Liver Disease
-
Guangzhou, Guangdong, ChinaHepatology Unit, Department of Infectious Diseases, Nanfang Hosp
Feb 4, 2021